Agustin A Garcia

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. ncbi Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer
    Agustin A Garcia
    University of Southern California, Keck School of Medicine, Kenneth Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA
    Gynecol Oncol 93:493-8. 2004
  2. ncbi Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer
    Agustin A Garcia
    University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, USA
    Int J Gastrointest Cancer 34:79-86. 2003
  3. ncbi Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study
    Agustin A Garcia
    Breast Cancer Program, Cedars Sinai Medical Center, Women s Cancer Research Institute, 8700 Beverly Boulevard Room 290 W, Los Angeles, CA 90048, USA
    Gynecol Oncol 96:810-7. 2005
  4. ncbi Phase I clinical trial of topotecan and pegylated liposomal doxorubicin
    Agustin A Garcia
    Division of Medical Oncology, University of Southern California Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90048, USA
    Cancer Invest 23:665-70. 2005
  5. ncbi Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis
    Agustin A Garcia
    University of Southern California Keck School of Medicine, Kenneth Norris Jr Comprehensive Cancer Center, Los Angeles, CA, USA
    Invest New Drugs 24:79-83. 2006
  6. ncbi Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors
    Syma Iqbal
    Department of Medical Oncology, University of Southern California Norris Cancer Center, Los Angeles, CA 90033, USA
    Am J Clin Oncol 34:27-31. 2011
  7. ncbi Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia
    Agustin A Garcia
    University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA
    J Clin Oncol 26:76-82. 2008
  8. ncbi Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule
    Agustin A Garcia
    Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Cancer Chemother Pharmacol 56:75-82. 2005
  9. ncbi Phase II study of gemcitabine and docetaxel in recurrent platinum resistant ovarian cancer
    Agustin A Garcia
    Kenneth Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    Cancer Invest 30:295-9. 2012
  10. ncbi Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab
    Anne M Schultheis
    University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA
    Clin Cancer Res 14:7554-63. 2008

Detail Information

Publications19

  1. ncbi Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer
    Agustin A Garcia
    University of Southern California, Keck School of Medicine, Kenneth Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA
    Gynecol Oncol 93:493-8. 2004
    ..The purpose of this study is to evaluate the activity of gemcitabine and weekly paclitaxel in patients with platinum-resistant ovarian cancer...
  2. ncbi Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer
    Agustin A Garcia
    University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, USA
    Int J Gastrointest Cancer 34:79-86. 2003
    ..Advanced pancreatic cancer has limited treatment options. 5-fluorouracil (5-FU) is frequently used in the treatment of pancreatic cancer. Preclinical studies suggest synergism between trimetrexate (TMTX),5-FU, and leucovorin (NFL)...
  3. ncbi Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study
    Agustin A Garcia
    Breast Cancer Program, Cedars Sinai Medical Center, Women s Cancer Research Institute, 8700 Beverly Boulevard Room 290 W, Los Angeles, CA 90048, USA
    Gynecol Oncol 96:810-7. 2005
    ....
  4. ncbi Phase I clinical trial of topotecan and pegylated liposomal doxorubicin
    Agustin A Garcia
    Division of Medical Oncology, University of Southern California Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90048, USA
    Cancer Invest 23:665-70. 2005
    ....
  5. ncbi Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis
    Agustin A Garcia
    University of Southern California Keck School of Medicine, Kenneth Norris Jr Comprehensive Cancer Center, Los Angeles, CA, USA
    Invest New Drugs 24:79-83. 2006
    ..The objective of this phase I study was to determine the maximal tolerated dose (MTD) of the combination of weekly docetaxel and exisulind in patients with advanced solid tumors...
  6. ncbi Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors
    Syma Iqbal
    Department of Medical Oncology, University of Southern California Norris Cancer Center, Los Angeles, CA 90033, USA
    Am J Clin Oncol 34:27-31. 2011
    ..The primary objective of this study was to determine the maximum tolerated dose (MTD) of pegylated liposomal doxorubicin (PLD) and docetaxel (T) administered in 4 week cycles in patients with advanced solid tumors...
  7. ncbi Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia
    Agustin A Garcia
    University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA
    J Clin Oncol 26:76-82. 2008
    ..A phase II trial was conducted to evaluate the antitumor activity and adverse effects of bevacizumab and metronomic oral cyclophosphamide in women with recurrent OC...
  8. ncbi Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule
    Agustin A Garcia
    Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Cancer Chemother Pharmacol 56:75-82. 2005
    ..CONCLUSIONS: The combination of weekly docetaxel and irinotecan is a well tolerated regimen and should be explored in phase II trials. This schedule maintains dose intensity and has limited myelosuppression...
  9. ncbi Phase II study of gemcitabine and docetaxel in recurrent platinum resistant ovarian cancer
    Agustin A Garcia
    Kenneth Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    Cancer Invest 30:295-9. 2012
    ..Excessive myelosuppression led to early closure. This was prevented by administering docetaxel on day 8 (instead of day 1) and prophylactic use of G-CSF...
  10. ncbi Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab
    Anne M Schultheis
    University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA
    Clin Cancer Res 14:7554-63. 2008
    ..This study was designed to evaluate the associations between angiogenesis gene polymorphisms and clinical outcome in ovarian cancer patients treated with low-dose cyclophosphamide and bevacizumab...
  11. ncbi A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group
    Agustin A Garcia
    Division of Medical Oncology, University of Southern California, Los Angeles, CA 90033, USA
    Gynecol Oncol 111:22-6. 2008
    ..A phase II study was conducted to evaluate the anti-tumor activity and adverse effects of weekly docetaxel in patients with previously treated endometrial cancer...
  12. ncbi Current status of signal transduction modulators in the treatment of gynecologic malignancies
    Shay Ashouri
    Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
    Curr Treat Options Oncol 8:383-92. 2007
    ..It is expected that other signal transduction modulators will also have substantial activity in gynecological tumors...
  13. ncbi A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study
    Agustin A Garcia
    University of Southern California, Los Angeles, CA, USA
    Gynecol Oncol 124:569-74. 2012
    ....
  14. ncbi Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study
    Agustin A Garcia
    Premiere Oncology, Santa Monica, CA, USA
    Am J Clin Oncol 30:428-31. 2007
    ..A phase II study was conducted to evaluate the antitumor activity and adverse effects of docetaxel in patients with previously treated squamous cell carcinoma of the cervix...
  15. ncbi Phase I escalation of gemcitabine combined with protracted oral etoposide in gynecologic malignancies: A Gynecologic Oncology Group study
    Agustin A Garcia
    Division of Medical Oncology, University of Southern California Norrris Comprehensive Cancer Center, Los Angeles 90089, USA
    Invest New Drugs 20:383-7. 2002
    ..This, combined with preclinical synergism, prompted the Gynecologic Oncology Group to determine the maximum tolerated dose (MTD) of this combination...
  16. ncbi Bevacizumab in the management of solid tumors
    Roy L Pañares
    University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, USA
    Expert Rev Anticancer Ther 7:433-45. 2007
    ..The duration and timing of bevacizumab's use is currently the focus of several ongoing clinical trials...
  17. ncbi Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients
    Bichlien Nguyen
    Department of Medicine, Todd Cancer Institute, Long Beach Memorial Medical Center, Long Beach, CA, USA
    Ann Surg Oncol 19:3257-63. 2012
    ....
  18. ncbi Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study
    Agustin A Garcia
    Premiere Oncology, 2020 Santa Monica Blvd Santa Monica, CA 90404, USA
    Gynecol Oncol 104:572-9. 2007
    ..To evaluate the anti-tumor activity and adverse events of capecitabine in advanced, persistent or recurrent squamous cell carcinoma of the cervix, and to explore biomarkers with the potential to predict capecitabine response and toxicity...
  19. ncbi Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status
    Michael S Gordon
    Arizona Cancer Center, Tuscon and Scottsdale, AZ, USA
    J Clin Oncol 24:4324-32. 2006
    ..CONCLUSION: Pertuzumab is well tolerated with a RR of 4.3% in heavily-pretreated OC patients. Further studies on pHER2 as a diagnostic are warranted...